Payment overview · 2025
General Payments
$376.93
19 reported records · 11 companies
Healthcare provider profile · identity verified
Stephen Snyder, MD
Allopathic & Osteopathic Physicians|Internal Medicine · LITTLE ROCK, AR · NPI 1053348870
Verified facts
What the public records show
CMS Open Payments records show Stephen Snyder, MD received $376.93 in general payments during 2025 across 19 reported records.
Dexcom, Inc. accounted for 19.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Paxlovid, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Trelegy Ellipta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $74.77 | 19.8% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $73.39 | 19.5% | 4 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $48.02 | 12.7% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $34.42 | 9.1% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $28.38 | 7.5% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $25.50 | 6.8% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $23.96 | 6.4% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $20.90 | 5.5% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $18.01 | 4.8% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $15.53 | 4.1% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $14.05 | 3.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $376.93 | 19 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $74.77 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $57.53 | 3 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $48.02 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $34.42 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $28.38 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $28.38 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $25.50 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $23.96 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $23.96 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $20.90 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $18.01 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $15.86 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $15.53 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $14.05 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $14.05 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 66 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 23 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 41 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
26 | 12 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
66 | 19 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
72 | 18 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
23 | 23 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1051 | 284 |
| Amlodipine Besylate | Amlodipine Besylate | 891 | 227 |
| Losartan Potassium | Losartan Potassium | 774 | 206 |
| Pantoprazole Sodium | Pantoprazole Sodium | 488 | 120 |
| Levothyroxine Sodium | Levothyroxine Sodium | 450 | 104 |
| Lisinopril | Lisinopril | 382 | 97 |
| Gabapentin | Gabapentin | 326 | 86 |
| Metformin Hcl | Metformin Hcl | 319 | 85 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 274 | 93 |
| Hydrochlorothiazide | Hydrochlorothiazide | 271 | 84 |
| Omeprazole | Omeprazole | 264 | 71 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 246 | 58 |
| Furosemide | Furosemide | 183 | 54 |
| Duloxetine Hcl | Duloxetine Hcl | 175 | 45 |
| Ozempic | Semaglutide | 168 | 34 |
| Metoprolol Tartrate | Metoprolol Tartrate | 167 | 48 |
| Tizanidine Hcl | Tizanidine Hcl | 160 | 40 |
| Sertraline Hcl | Sertraline Hcl | 128 | 43 |
| Potassium Chloride | Potassium Chloride | 124 | 40 |
| Metoprolol Succinate | Metoprolol Succinate | 116 | 32 |
| Carvedilol | Carvedilol | 115 | 34 |
| Clopidogrel | Clopidogrel Bisulfate | 113 | 26 |
| Tamsulosin Hcl | Tamsulosin Hcl | 107 | 34 |
| Ezetimibe | Ezetimibe | 104 | 25 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 103 | 26 |
| Trazodone Hcl | Trazodone Hcl | 102 | 25 |
| Mirtazapine | Mirtazapine | 99 | 24 |
| Fluticasone Propionate | Fluticasone Propionate | 98 | 28 |
| Famotidine | Famotidine | 93 | 31 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 90 | 29 |
| Allopurinol | Allopurinol | 89 | 34 |
| Metformin Hcl Er | Metformin Hcl | 88 | 26 |
| Escitalopram Oxalate | Escitalopram Oxalate | 84 | 20 |
| Montelukast Sodium | Montelukast Sodium | 80 | 20 |
| Spironolactone | Spironolactone | 79 | 20 |
| Citalopram Hbr | Citalopram Hydrobromide | 77 | 21 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 76 | 22 |
| Mounjaro | Tirzepatide | 75 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 75 | 22 |
| Alprazolam | Alprazolam | 74 | 20 |
| Eliquis | Apixaban | 72 | 18 |
| Fluoxetine Hcl | Fluoxetine Hcl | 71 | 16 |
| Simvastatin | Simvastatin | 71 | 21 |
| Jardiance | Empagliflozin | 70 | 22 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 67 | 19 |
| Farxiga | Dapagliflozin Propanediol | 66 | 19 |
| Glimepiride | Glimepiride | 66 | 17 |
| Doxycycline Hyclate | Doxycycline Hyclate | 63 | 58 |
| Hydralazine Hcl | Hydralazine Hcl | 62 | 14 |
| Buspirone Hcl | Buspirone Hcl | 61 | 17 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 58 | 11 |
| Clonazepam | Clonazepam | 55 | 11 |
| Methylprednisolone | Methylprednisolone | 55 | 50 |
| Pregabalin | Pregabalin | 53 | 12 |
| Nifedipine Er | Nifedipine | 51 | 15 |
| Atenolol | Atenolol | 47 | 15 |
| Gemtesa | Vibegron | 47 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 47 | 18 |
| Lorazepam | Lorazepam | 46 | 11 |
| Clonidine Hcl | Clonidine Hcl | 45 | 14 |
| Cephalexin | Cephalexin | 44 | 33 |
| Valsartan | Valsartan | 44 | 14 |
| Glipizide | Glipizide | 42 | suppressed |
| Bupropion Xl | Bupropion Hcl | 41 | suppressed |
| Chlorthalidone | Chlorthalidone | 41 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 41 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 41 | suppressed |
| Meloxicam | Meloxicam | 39 | 17 |
| Oxybutynin Chloride | Oxybutynin Chloride | 39 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 39 | 15 |
| Ciclopirox | Ciclopirox Olamine | 37 | 21 |
| Januvia | Sitagliptin Phosphate | 37 | suppressed |
| Memantine Hcl | Memantine Hcl | 37 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 37 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 37 | suppressed |
| Baclofen | Baclofen | 35 | 11 |
| Benazepril Hcl | Benazepril Hcl | 35 | suppressed |
| Finasteride | Finasteride | 35 | 12 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 34 | 18 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 33 | 30 |
| Donepezil Hcl | Donepezil Hcl | 31 | suppressed |
| Repatha Sureclick | Evolocumab | 31 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 31 | suppressed |
| Glipizide Er | Glipizide | 29 | 12 |
| Lansoprazole | Lansoprazole | 29 | suppressed |
| Irbesartan | Irbesartan | 28 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 27 | suppressed |
| Indapamide | Indapamide | 27 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 27 | suppressed |
| Verapamil Er | Verapamil Hcl | 27 | suppressed |
| Linzess | Linaclotide | 26 | 12 |
| Synthroid | Levothyroxine Sodium | 26 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 25 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 25 | suppressed |
| Estradiol | Estradiol | 25 | suppressed |
| Folic Acid | Folic Acid | 25 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 25 | 19 |
| Klor-Con M20 | Potassium Chloride | 24 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 23 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 23 | 23 |
| Topiramate | Topiramate | 23 | suppressed |
| Amoxicillin | Amoxicillin | 22 | 22 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 22 | suppressed |
| Sucralfate | Sucralfate | 21 | suppressed |
| Levetiracetam | Levetiracetam | 20 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 20 | 13 |
| Symbicort | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 19 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 19 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 19 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 19 | suppressed |
| Ibuprofen | Ibuprofen | 19 | suppressed |
| Lovastatin | Lovastatin | 19 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 19 | suppressed |
| Ramipril | Ramipril | 19 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 19 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 18 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 18 | suppressed |
| Telmisartan | Telmisartan | 18 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 18 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 17 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 17 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 17 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 17 | suppressed |
| Aripiprazole | Aripiprazole | 16 | suppressed |
| Bumetanide | Bumetanide | 16 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 16 | suppressed |
| Ondansetron Odt | Ondansetron | 16 | 13 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 16 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 16 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 15 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 15 | suppressed |
| Diazepam | Diazepam | 15 | suppressed |
| Digoxin | Digoxin | 15 | suppressed |
| Prednisone | Prednisone | 15 | 11 |
| Brimonidine Tartrate | Brimonidine Tartrate | 14 | suppressed |
| Combigan | Brimonidine Tartrate/Timolol | 14 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 14 | suppressed |
| Nystatin | Nystatin | 14 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 14 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 13 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 13 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Latanoprost | Latanoprost | 13 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | 13 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 13 | suppressed |
| Temazepam | Temazepam | 13 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | 11 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Cefdinir | Cefdinir | 11 | suppressed |
| Dapagliflozin-Metformin Er | Dapaglifloz Propaned/Metformin | 11 | suppressed |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 11 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 11 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $376.93 · 19 records | Dexcom, Inc. | AIRSUPRA, AREXVY, CAPVAXIVE, Dexcom G6 Transmitter, FARXIGA, GARDASIL 9, Kerendia, LEQVIO, Leqembi, PAXLOVID, QULIPTA, TRELEGY ELLIPTA, TZIELD, The Cologuard Plus Collection Kit, UBRELVY | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error